Protagonist Therapeutics Inc(PTGX)
盘后82.260.27+0.33%18:56 EST
81.99-2.76-3.26%
行情数据延迟15分钟
- 最新
- 推荐
暂无内容公司概况
公司名称Protagonist Therapeutics Inc所属市场NASDAQ成立日期- -员工人数- -办公地址- -邮政编码- -联系电话- -联系传真- -公司概况Protagonist Therapeutics, Inc.在特拉华州注册成立于2006年8月22日，总部位于加利福尼亚州米尔皮塔斯。该公司是一家生物制药公司，其基于多肽的新化学实体rusfertide和JNJ-2113（原名PN-235）处于不同的开发阶段，均源自专有的发现技术平台。该公司的临床项目分为两大类疾病：（一）血液学和血液疾病，以及（二）炎症和免疫调节疾病。- 01-12Form 8-K - Current report重要事件披露Form 8-K - Current report
- 2025-11-06Form 10-Q - Quarterly report [Sections 13 or 15(d)]季度报告Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 2025-11-06Form 8-K - Current report重要事件披露Form 8-K - Current report
- 2025-10-10Form 144 - Report of proposed sale of securities关联方拟减持公告Form 144 - Report of proposed sale of securities
- 2025-09-22Form 144 - Report of proposed sale of securities关联方拟减持公告Form 144 - Report of proposed sale of securities
- 2025-08-27Form 144 - Report of proposed sale of securities关联方拟减持公告Form 144 - Report of proposed sale of securities
- 2025-08-06Form 10-Q - Quarterly report [Sections 13 or 15(d)]季度报告Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 2025-08-06Form 8-K - Current report重要事件披露Form 8-K - Current report
- 2025-07-22Form 144 - Report of proposed sale of securities关联方拟减持公告Form 144 - Report of proposed sale of securities
- 2025-06-26Form 8-K - Current report重要事件披露Form 8-K - Current report
- 2025-06-10Form 144 - Report of proposed sale of securities关联方拟减持公告Form 144 - Report of proposed sale of securities
- 2025-06-09Form 144 - Report of proposed sale of securities关联方拟减持公告Form 144 - Report of proposed sale of securities
- 2025-05-06Form 10-Q - Quarterly report [Sections 13 or 15(d)]季度报告Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 2025-05-06Form 8-K - Current report重要事件披露Form 8-K - Current report
- 2025-03-20Form 8-K - Current report重要事件披露Form 8-K - Current report
- 分时
- 5日
- 日
- 周
- 月
数据加载中...
最高
84.67
今开
84.51
量比
0.75
最低
81.47
昨收
84.75
换手率
1.54%